Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate whether liraglutide added to treat-to-target insulin improves glycemic control and reduces insulin requirements and body weight in subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS: A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin. RESULTS: HbA1c level was reduced 0.34–0.54% (3.7–5.9 mmol/mol) from a mean baseline of 8.2% (66 mmol/mol), and significantly more for liraglutide 1.8 and 1.2 mg compared with placebo (estimated treatment differences [ETDs]: 1.8 mg liraglutide −0.20% [95% CI −0.32; −0.07]; 1.2 mg liraglutide −0.15% [95% CI −0.27; −0.03]; 0.6 mg liraglutide −0.09% [95% CI −0.21; 0.03]). Insulin doses were reduced by the addition of liraglutide 1.8 and 1.2 mg versus placebo (estimated treatment ratios: 1.8 mg liraglutide 0.92 [95% CI 0.88; 0.96]; 1.2 mg liraglutide 0.95 [95% CI 0.91; 0.99]; 0.6 mg liraglutide 1.00 [95% CI 0.96; 1.04]). Mean body weight was significantly reduced in all liraglutide groups compared with placebo ETDs (1.8 mg liraglutide −4.9 kg [95% CI −5.7; −4.2]; 1.2 mg liraglutide −3.6 kg [95% CI −4.3; −2.8]; 0.6 mg liraglutide −2.2 kg [95% CI −2.9; −1.5]). The rate of symptomatic hypoglycemia increased in all liraglutide groups (estimated rate ratios: 1.8 mg liraglutide 1.31 [95% CI 1.07; 1.59]; 1.2 mg liraglutide 1.27 [95% CI 1.03; 1.55]; 0.6 mg liraglutide 1.17 [95% CI 0.97; 1.43]), and hyperglycemia with ketosis increased significantly for liraglutide 1.8 mg only (event rate ratio 2.22 [95% CI 1.13; 4.34]). CONCLUSIONS: Liraglutide added to insulin therapy reduced HbA1c levels, total insulin dose, and body weight in a population that was generally representative of subjects with type 1 diabetes, accompanied by increased rates of symptomatic hypoglycemia and hyperglycemia with ketosis, thereby limiting clinical use in this group.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The largest clinical trials of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in type 1 diabetes have been conducted with liraglutide 1.8 mg daily, and results showed modest A1C reductions ($0.4%), decreases in weight ($5 kg), and reductions in insulin doses (71,72).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [71]
In the citing paper
“However, increased rates of hypoglycemia and ketosis were shown.”
In the citing paper
“The largest clinical trials in people with type 1 diabetes were conducted with liraglutide and showed decreases in HbA 1c at daily doses of 1.8 mg (0.2-0.4% [2-4 mmol/mol]), decreases in weight (5 kg), and reductions in insulin doses (257,258).”
In the citing paper
“GLP1 receptor agonists reduce bodyweight and insulin dose, with modest improvements in glycaemic control.[93][94][95][96]”
From The future of type 1 diabetes therapy (2025) · cites this paper as [93]
In the citing paper
“Adding SGLT2 inhibitors at a lower than usual dose to insulin therapy in T1DM may reduce glucose variability and facilitate glucose control, thereby reducing insulin doses and hypoglycaemia.803”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [803]
Citations
Cites
Hyperglycemic crises in adult patients with diabetes
Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N. (2009) · Diabetes Care · doi:10.2337/dc09-9032 · Cited by 2,062
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 3×
“****EAC-confirmed malignant neoplasms were all skin cancers (two malignant melanomas; one basal cell carcinoma) using ADA classification of hypoglycemia (13).”
BackgroundMethodInfluentialMiller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Rosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664 · cited 1×
“drate levels may be reduced as a result of urinary excretion (23,24).”
BackgroundWeinstock, R. S., Xing, D., Maahs, D. M., Michels, A., Rickels, M. R., Peters, A. L., Bergenstal, R. M., Harris, B., DuBose, S. N., Miller, K. M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1589 · Cited by 338
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304
Implementation of Treatment Protocols in the Diabetes Control and Complications Trial
Diabetes Control and Complications Trial Research Group (1995) · Diabetes Care · doi:10.2337/diacare.18.3.361 · Cited by 283
Purnell, J. Q., Zinman, B., & Brunzell, J. D. (2013) · Circulation · doi:10.1161/circulationaha.111.077487 · Cited by 267
Self-citationDejgaard, T. F., Frandsen, C. S., Hansen, T. S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A. K., Holst, J. J., Tarnow, L., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00436-2 · Cited by 179
Jones, A. G., McDonald, T. J., Shields, B. M., Hill, A. V., Hyde, C. J., Knight, B. A., & Hattersley, A. T. (2016) · Diabetes Care · doi:10.2337/dc15-0258 · Cited by 178
Cited by
Items 201–300 of 347
Abdel‐Rahman, S. M., Al-Shiab, R., Shah, E., Güldan, M., Ak, A. B., Yilmaz, Z. Y., Fidan, D. G., Özbek, L., & Kanbay, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70506 · Cited by 7
Safety of GLP-1 receptor agonists in type 1 diabetes: a systematic review and meta-analysis.
Kateel, R., Parida, A., Chogtu, B., & Holla, S. N. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113270 · Cited by 6
Joshi, N., Baloch, K. M., Rukh, S., Khan, A. M., Muskan, F., Kumari, V., Khan, H., Zeeshan, M., Azam, G., Khalid, S., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002712 · Cited by 6
Rajab, A. M., Pearson, S. M., & Ajjan, R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16332 · Cited by 6
Maguolo, A., Rioda, M., Zusi, C., Emiliani, F., Olivieri, F., Piona, C. A., Marigliano, M., Orsi, S., Morandi, A., & Maffeis, C. (2022) · Hormone Research in Paediatrics · doi:10.1159/000527520 · Cited by 8
Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes
Raven, L. M., Greenfield, J. R., & Muir, C. A. (2022) · JCEM Case Reports · doi:10.1210/jcemcr/luac017 · Cited by 6
Melander, S. A., Larsen, A. T., Karsdal, M. A., & Henriksen, K. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16329 · Cited by 6
A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus
AlHabeeb, W., Elasfar, A., Kinsara, A. J., Aljizeeri, A. H., Jelaidan, I., Alghalayini, K. W., AlKheraiji., M. F., Akbar, M. A. J., Lawand, S., Alyousif, S. M., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1407 · Cited by 11
Vendrame, F., Calhoun, P. M., Bocchino, L. E., Pratley, R. E., & Casu, A. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107884 · Cited by 5
Silva, V. B., Fonseca, L., Duarte, D. B., Puga, F. M., Assuncao, G., Garrido, S., Teixeira, S., Vilaverde, J., & Cardoso, M. H. (2023) · Endocrine Regulations · doi:10.2478/enr-2023-0018 · Cited by 5
A Federated Database for Obesity Research: An IMI-SOPHIA Study
Delfin, C., Dragan, I., Kuznetsov, D., Tajes, J. F., Smit, F., Coral, D., Farzaneh, A., Haugg, A., Hungele, A., Niknejad, A., et al. (2024) · Life · doi:10.3390/life14020262 · Cited by 6
Targeting cardiometabolic risk in type 1 diabetes through incretin physiology
Frampton, R., HOCKING, S. L., SNAITH, J. R., & Greenfield, J. R. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.06.004 · Cited by 4
Obesity and the Gut-Brain Axis in Type 1 Diabetes Mellitus: Terra Incognita?
Argyrakopoulou, G., Gitsi, E., Dalamaga, Μ., & Kokkinos, A. D. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00654-8 · Cited by 4
Gonzalez, F., Reid, M. W., Garcia, J. F., Raymond, J. K., & Chao, L. C. (2025) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2025-0568 · Cited by 5
Garg, S., Kim, S., Ford, A. M., Loesch, J., Valencia, S. O., Zhou, K., & Lembo, A. J. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251403555 · Cited by 7
Wu, Y., Lu, Y., Yang, S., & Zhang, Q. (2021) · Journal of International Medical Research · doi:10.1177/03000605211066306 · Cited by 5
Interventions Targeting Insulin Resistance in Patients with Type 1 Diabetes: A Narrative Review
Herascu, A., Avram, V. F., Gaiţă, L., Sima, A. C., Reurean‐Pintilei, D., & Timar, B. (2024) · Medicina · doi:10.3390/medicina60122067 · Cited by 6
Hundert Jahre – Insulin bleibt aktuell und notwendig
Landgraf, R., & Aberle, J. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1386-0011 · Cited by 8
Type 1 Diabetes and Cardiovascular Health
Pesantez, M., Ebekozien, O. A., & Vendrame, F. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.07.003 · Cited by 5
Aung, N. L. (2024) · Clinical Diabetes · doi:10.2337/cd24-0038 · Cited by 5
Expanding Treatment Options for Improving Health Outcomes in Type 1 Diabetes
Garg, S. K. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.1807 · Cited by 4
Integrating Omics into Functional Biomarkers of Type 1 DiabetesPreprint
Long, S. A., & Linsley, P. S. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041602 · Cited by 7
Managing adults with screen-detected islet autoantibody positivity: a pragmatic framework
Thomas, N. J., Tatović, D., Jones, A. G., & Narendran, P. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00260-8 · Cited by 6
Pasqua, M., Tsoukas, M. A., & Haidar, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70213 · Cited by 5
Tentolouris, A., Koufakis, T., & Fousteris, E. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00693-9 · Cited by 5
The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults
Lunati, M. E., Cimino, V., Bernasconi, D. P., Romano, C., Disoteo, O., Rossi, A., Tinari, C., Fiorina, R. M., Gandolfi, A., Morpurgo, P. S., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag072 · Cited by 4
Tentolouris, A., Filippatos, C., Tepetes, N.-I., Gavriatopoulou, M., Terpos, E., Briasoulis, Α., Stamatelopoulos, K. S., & Filippatos, T. D. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70841 · Cited by 4
Glucagon-like peptide-1 and impaired counterregulatory responses to hypoglycemia in type 1 diabetes
Rocha, G. R., & de Melo, F. F. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.99928 · Cited by 4
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials
Min, T., & Bain, S. C. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2188191 · Cited by 4
Johansen, N. J., Dejgaard, T. F., Lund, A., Vilsbøll, T., Andersen, H. U., & Knop, F. K. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-021861 · Cited by 3
Effect of liraglutide on microcirculation in rat model with absolute insulin deficiency
Иванов, А. Н., Lagutina, D. D., Saveleva, М. S., Popyhova, E. B., Stepanova, T. V., Савкина, А. А., Pylaev, T. E., & Kuznetsova, N. A. (2021) · Microvascular Research · doi:10.1016/j.mvr.2021.104206 · Cited by 3
Thalange, N. K. S., Aldhouse, N. V. J., Kitchen, H., Howard, D., Tutkunkardas, D., & Håkan‐Bloch, J. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0305-0 · Cited by 4
Targeting postprandial glycaemia in children with diabetes: O pportunities and challenges
Geyer, M. C., Rayner, C. K., Horowitz, M., & Couper, J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13141 · Cited by 5
Non-insulin therapies in addition to insulin in Type 1 DM treatment
Llano, A., & McKay, G. A. (2020) · British Medical Bulletin · doi:10.1093/bmb/ldaa011 · Cited by 3
Steenackers, N., Sparsø, T., Charleer, S., Block, C. E. M. D., Cock, D. D., Delfin, C., Mathieu, C., Nobels, F. R. E., Pazmiño, S., Rosen, J., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15886 · Cited by 2
Self-citationGLP-1 agonists in Type 1 diabetes – Indications and use
Panjawatanan, P., & Comi, R. J. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100591 · Cited by 3
Moosavi, A., Tabrizi, Z. A., Eghbali, Z., Barzegari, A., Hejazian, S. M., Kheiri, S., & Seyedmadani, S. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112359 · Cited by 2
The role of GLP1 receptor agonists in adult-onset type 1 diabetes mellitus
Popovic, D. S., Koufakis, T., Patoulias, D., Maltese, G., & Παπάνας, Ν. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01154-4 · Cited by 3
Lisco, G., Tullio, A. D., Disoteo, O., Armigliato, M., Guastamacchia, E., Marucci, S., Pergola, G. D., Papini, E., Chianelli, M., Frasoldati, A., et al. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70073 · Cited by 2
van Laar, A., Gallardo‐Nuell, L., Pazmiño, S., Visser, M. M., Mertens, A. C., Vangoitsenhoven, R., Gillard, P., Al‐Ozairi, E., le Roux, C. W., Rosen, J., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103589 · Cited by 4
Self-citationRevolutionizing Diabetes Care: From Tech to Therapeutics
Aktürk, H. K., WATERMAN, L. A., & Cobry, E. C. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s580423 · Cited by 2
GLP-1 and GIP in Type 1 Diabetes Therapy: A Time for Reappraisal?
Piras, G., Brasili, S., Demontis, D., Sala, L. D., Cocchiara, F., Maggi, D. C., & Arecco, A. (2026) · Diabetology · doi:10.3390/diabetology7030050 · Cited by 2
Mirghani, H. O., Albishi, L. A., & Alblewi, S. M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1758755 · Cited by 2
Tirzepatide for Excess Weight in Adults With Type 1 Diabetes Using MiniMed 780G
Fano, M. D., Tortoriello, R., Rucco, S., Corio, S., Manco, M., Guerrini, E., & Porcellati, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71002 · Cited by 2
Pasqua, M., Odabassian, M., Tsoukas, M. A., & Haidar, A. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231176302 · Cited by 2
Testing a new platform to screen disease-modifying therapy in type 1 diabetes
Lord, S. M., Bahnson, H. T., Greenbaum, C. J., Liljenquist, D. R., Virostko, J. M., & Speake, C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0293268 · Cited by 2
Finerenone in type 1 diabetes and chronic kidney disease: short-term efficacy and safety insights
Qiu, D., Wang, J., Li, A., Zhang, W., Du, X., Wang, G., & Jiang, S. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04773-y · Cited by 2
The 80th annual (virtual) conference of the American Diabetes Association: June 12–16, 2020
Suliman, M., Mohammed, N., & Suliman, S. (2020) · Ibnosina Journal of Medicine and Biomedical Sciences · doi:10.4103/ijmbs.ijmbs_106_20 · Cited by 2
den Mooter, L. V., Caerels, S., & Mathieu, C. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1450387 · Cited by 2
Self-citationRole of Noninsulin Therapies in the Treatment of Type 1 Diabetes
Lingow, S. E., Burke, S. D., Brooks, A. D., & Rafferty, P. S. (2018) · Diabetes Spectrum · doi:10.2337/ds18-0058 · Cited by 2
Yamada, T., Mori, R., Hosoe, J., Shojima, N., Kamata, R., Ishinohachi, K., Yamauchi, T., Tanikawa, Y., & Kadowaki, T. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013164 · Cited by 2
Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Pietraszek, A. (2020) · Current Drug Safety · doi:10.2174/1574886315666200902154736 · Cited by 2
Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?
Aeng, E. S. Y., Boucher, M., & Severn, M. (2016) · Cited by 2
Diabetes mellitus tipo 1: Una perspectiva para estudiantes de Ciencias de la Salud
Zambrano, D. Y., Gonzalez, M. A., Farfán-Cano, H. R., Farfán-Cano, G. G., & Moreira, K. M. C. (2022) · Revista Ecuatoriana de Ciencia Tecnología e Innovación en Salud Pública · doi:10.31790/inspilip.v4i3.247 · Cited by 3
Borg, D. J., Faridi, P., Giam, K., Reeves, P., Fotheringham, A. K., McCarthy, D. A., Leung, S. S., Ward, M. S., Harcourt, B. E., Ayala, R., et al. (2021) · Metabolites · doi:10.3390/metabo11070426 · Cited by 2
Popovic, D. S., Stoian, A. P., & Παπάνας, Ν. (2023) · Endocrine · doi:10.1007/s12020-022-03294-3 · Cited by 2
Mirghani, H. O. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i11.2167 · Cited by 2
Ning, X., Munir, K. M., & Davis, S. N. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2439501 · Cited by 2
Nakhoul, L., Nakhoul, T. B., Azar, M. A., Harb, F., & Nakhoul, N. (2025) · PLoS ONE · doi:10.1371/journal.pone.0332191 · Cited by 1
Wang, W. T., & Loh, W. J. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000940 · Cited by 2
Pasqua, M., Doumat, J., Tsoukas, M. A., & Haidar, A. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.10.175 · Cited by 1
Hirai, T., Kitada, M., Endo, K., Hayashi, K., & Suzuki, T. (2025) · Cureus · doi:10.7759/cureus.96335 · Cited by 1
Thiyagarajan, S. K., Wall‐Wieler, E., Liu, Y., Zheng, F., & Edwards, M. (2026) · Obesity Surgery · doi:10.1007/s11695-025-08467-3 · Cited by 2
Sánchez-García, D., Luna‐Garza, Y., Saavedra-Castillo, E., Gómez-Martínez, G., Diaz-Sallas, M., Ortega‐Valdez, A. C., Martínez‐Mendoza, Z. F., Reyes‐Valdez, K. R., Huitron‐Ramirez, R. A., Martinez‐Rentería, J. P., et al. (2026) · Diabetic Medicine · doi:10.1111/dme.70222 · Cited by 2
Pandey, A., REPETTO, E., Perkins, C., Rossing, P. R., & Caramori, M. L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70597 · Cited by 3
Managing Obesity in Individuals with Cardiovascular Disease: Are We Missing the Obvious?
Gao, M., Kurala, T. S., & Ajjan, R. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.53 · Cited by 1
Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus
Kugathasan, L., Katz, A., Muskiet, M. H. A., Sridhar, V. S., Scott, J., Yi, T. W., & Cherney, D. Z. I. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106547 · Cited by 2
Saeed, Z. I., & Shah, V. N. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.006 · Cited by 1
Wang, Y., He, S., Yang, H., Zhang, J., Yu, L., Xiong, J., Li, X., Qiu, J., & Ma, B. (2026) · Biology · doi:10.3390/biology15171472 · Cited by 1
GLP-1-Analoga auch für Typ-1-Diabetiker?
Stiefelhagen, P. (2016) · Info Diabetologie · doi:10.1007/s15034-016-0997-7 · Cited by 1
Developments in the Management of Type 1 and Type 2 Diabetes
Mathieu, C. (2018) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2018.14.2.13 · Cited by 1
Self-citationAberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2312-0389 · Cited by 1
Иванов, А. Н., Antipova, O. N., Савкина, А. А., Kiriyazi, T. S., Stepanova, T. V., Lagutina, D. D., & Kuznetsova, N. A. (2020) · Regional blood circulation and microcirculation · doi:10.24884/1682-6655-2020-19-4-61-69 · Cited by 1
Adjuvant therapy in type 1 diabetes mellitus
Cichocka, E., Maj-Podsiadło, A., & Gumprecht, J. (2021) · Endokrynologia Polska · doi:10.5603/ep.a2021.0003 · Cited by 1
Can exenatide flatten the post-prandial glucose curve in type 1 diabetes?
Boughton, C. K., & Hovorka, R. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3654
SGLT-Hemmer als therapeutische Option bei Patienten mit Typ 1 Diabetes mellitus
Sourij, C., Obermayer, A. M., & Sourij, H. (2018) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-018-0050-7
Buse, J. B. (2018) · US Endocrinology · doi:10.17925/use.2018.14.2.54
Jermendy, G. (2019) · Diabetologia Hungarica · doi:10.24121/dh.2019.9
SGLT inhibitors for type 1 diabetes: a finely balanced matter?
Morris, D. (2020) · Independent Nurse · doi:10.12968/indn.2020.4.14 · Cited by 1
Doggrell, S. A. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3702
Thivolet, C. H. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.07.004
When and how to Use A Glp-1 ra With Long- or Ultralong-Acting Basal Insulin in T2Dm
Bode, B. W. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)42965-9
Self-citationSchandl, L., & Winkler, G. (2020) · Diabetologia Hungarica · doi:10.24121/dh.2020.19
Garber, A. J. (2016) · Endocrine Practice · doi:10.4158/1934-2403-22.s5.1
Adjuvant therapy in type 1 diabetes mellitus — choice or necessity in the COVID-19 pandemic?
Cichocka, E. (2021) · Endokrynologia Polska · doi:10.5603/ep.a2021.0022
Role of Glucagon-like peptide-1 “Liraglutide” in Management of Type 1 Diabetes
Sehly, A. J. A., Altemani, R. F. H., Alharthi, Y. H. J., Alhwiti, A. G. S., Bedaiwi, A. A. A., Alqulayti, W. M., Alshuwaier, R. A. I., Alaql, A., & Ajwah, I. (2021) · International Journal of Pharmaceutical and Phytopharmacological Research · doi:10.51847/skbdqro7ng
Kombinationstherapien mit Insulin bei Typ-1-Diabetes
Gallwitz, B. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00795-z
Therapeutic potential of zein-based nanoparticles
Reboredo, C. (2022) · doi:10.15581/10171/62894
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_20 · Cited by 1
Popyhova, E. B., Stepanova, T., Савкина, А. А., Lagutina, D. D., & Иванов, А. Н. (2022) · Saratov Fall Meeting: Optical and Nanotechnologies for Biology and Medicine (SFM) · doi:10.1117/12.2624388
Advances in Biological and Clinical Research of GLP-1 Receptor Agonists
李, 鑫. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.124430
Glucagon Like Peptide-1: More than Glucose Control and Weight ReductionPreprint
Chen, Y., Shao, S., Zhang, X., Xu, Q., & Pan, R. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4161722
Current Strategies of New Drugs for Diabetes Management
Sarfraz, M., Hafizur, R. M., Ullah, H., Sajid, S., Akhtar, R. W., Noreen, M., Perveen, S., & Khan, M. U. (2023) · Frontiers in clinical drug research. Diabetes and obesity · doi:10.2174/9789815123586123070005
Future Role of Non-Insulin Antihyperglycemic Agents in the Management of Type 1 Diabetes Mellitus
Senior, P. A. (2023) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2023.1211
Heald, A. H., Warner-Levy, J. J., Belston, L., Habte‐Asres, H. H., Horne, L., Metters, A., Whyte, M., & Gibson, M. (2023) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000293
Tsoukas, M. A. (2023) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2023.1318
Il ruolo dello svuotamento gastrico nell’omeostasi e nella controregolazione glucidica
Scientifica, D., Squatrito, S., Direttore, C., & Melloni, R. S. (2024) · il Diabete · doi:10.30682/ildia2304b
Raven, L. M. (2024) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2024.03.007 · Cited by 1
Deniz, M. S. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1006990 · Cited by 1
Cheng, Y., Li, H., Liu, X., Jin, X., Han, J., Du, J., & Xu, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1381248
Metadata
- Authors
- Mathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., Bode, B., & for the ADJUNCT ONE Investigators
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Mount Sinai Hospital (CA)
- Capio St. Görans Hospital and the Karolinska Institute, Stockholm, Sweden
- Health Sciences Centre (CA)
- The Royal Melbourne Hospital (AU)
- Novo Nordisk (Denmark) (DK)
- Atlanta Diabetes Associates (US)
- Corresponding author
- Mathieu, Chantal
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-08-09
- Volume
- 39
- Issue
- 10
- Pages
- 1702-1710
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2514658869
- Cited by
- 347
- References
- 26
- Citations by year
- 2026: 52 · 2025: 56 · 2024: 49 · 2023: 28 · 2022: 23 · 2021: 28 · 2020: 34 · 2019: 27 · 2018: 26 · 2017: 17 · 2016: 7
- FWCI
- 25.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion)
- Funders
- Novo Nordisk A/S (NN9211-3919)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- liraglutide, type 1 diabetes, insulin therapy, glycemic control, HbA1c, insulin dose reduction, weight loss, GLP-1 receptor agonists, adjunctive therapy, drug safety, hypoglycemia, nausea, gastrointestinal adverse effects, drug discontinuation
- MeSH terms
- Liraglutide, Adult, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Male, Middle Aged, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.